The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Jul. 2, 5:28 AM

Slide #25. BioTime, Inc. Secondary Offering

Company: BioTime, Inc. (AMEX:BTX)
Date announced: 6/15/2016
Shares Offered: 7,322,176
Date of Pricing: 6/16/2016
Price Per Share: $2.39
Secondary Offering Details: BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 6/16- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public offering of 7,322,176 shares of its common stock at a public offering price of $2.39 per share. The gross proceeds to BioTime, Inc. from this offering are expected to be approximately $17.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioTime, Inc. The offering is expected to close on or about June 21, 2016, subject to customary closing conditions. BioTime, Inc. has also granted to the underwriters a 30-day option to purchase from it up to an additional 1,098,326 shares of its common stock.

BioTime is a biotechnology company focused on regenerative medicine; specifically human embryonic stem cell and induced pluripotent stem cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. Co. and its subsidiaries are developing stem cell products for research and therapeutic use. Co.'s primary therapeutic products are based on its HyStem® hydrogel technology and include Renevia™, a product to facilitate cell transplantation; ReGlyde™, a product under development for tendon surgery applications; and Premvia™, for use in wound-management.

BTX SEC Filing Email Alerts Service

Open the BTX Page at The Online Investor »

Company Name:  BioTime Inc
Website:  www.biotimeinc.com
Sector:  Biotechnology
Number of ETFs Holding BTX:  12
Total Market Value Held by ETFs:  $4.31M
Total Market Capitalization:  $237.00M
% of Market Cap. Held by ETFs:  1.82%
 

Open the BTX Page at The Online Investor (in a new window) »

July 2, 2016    5:28 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
85th percentile
(ranked higher than approx. 85% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.